Get the latest news and hear from families on our blog.
The ARRE Foundation is excited to announce a $545,000 research investment in 2025, bringing our total commitment to ASXL-related disorders to $1.3 million since 2018. This funding will support clinical studies, expand the ASXL Natural History Study and Biobank, and advance research into potential treatments, including a drug screening program using FDA-approved drugs. Together with the ASXL family community and dedicated researchers, we’re driving progress toward better care and therapies for Bohring-Opitz, Shashi-Pena, and Bainbridge-Ropers syndromes.
Two recent case reports document the successful use of pregabalin (Lyrica) to treat challenges related to Bainbridge-Ropers Syndrome (ASXL3-related disorder), including extreme behaviors and suspected pain episodes.
The ARRE Foundation announces the appointment of Sarah Scott as the new Family Education and Engagement Coordinator. Sarah brings a wealth of experience with her background in social work and her deep personal connection to the ASXL community.
We publish a newsletter for the ASXL community monthly. Sign up for our mailing list to receive our newsletter and other updates by email.
